Fischer Medical Ventures Ltd

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, witnessed a sharp decline on 10 Feb 2026, hitting its lower circuit limit with a maximum daily loss of 4.98%. The stock closed at ₹43.5, down ₹2.18 from the previous close, reflecting intense selling pressure and panic among investors despite recent gains.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, surged to hit its upper circuit limit on 6 Feb 2026, propelled by robust buying interest and sustained investor enthusiasm. The stock closed at ₹44.09, marking a maximum daily gain of 4.99%, significantly outperforming its sector and the broader market indices.

Fischer Medical Ventures Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a nuanced improvement in its technical indicators and financial performance despite ongoing valuation concerns and management efficiency challenges. The upgrade, effective from 4 February 2026, is driven primarily by a shift in technical trends and steady quarterly financial results, signalling cautious optimism among analysts.

Fischer Medical Ventures Ltd has experienced a notable shift in its technical parameters, signalling a subtle change in price momentum despite a complex mix of bullish and bearish indicators. The stock’s recent 5.00% day gain to ₹40.35, coupled with an upgrade in its Mojo Grade from Sell to Hold, highlights evolving market sentiment amid a challenging commodity chemicals sector backdrop.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, surged to hit its upper circuit limit on 4 February 2026, closing at ₹40.27, marking a 4.98% gain on the day. This sharp rally was driven by robust buying interest, significant unfilled demand, and a regulatory freeze on further trading, underscoring heightened investor enthusiasm despite a recent downgrade in its Mojo Grade to Sell.

Fischer Medical Ventures Ltd, a small-cap player in the commodity chemicals sector, surged to hit its upper circuit limit on 3 February 2026, propelled by robust buying interest and a significant intraday gain of 4.98%. The stock’s performance outpaced both its sector and the broader Sensex, signalling renewed investor confidence despite a recent downgrade in its mojo grade.

Fischer Medical Ventures Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 January 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 01 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Fischer Medical Ventures Ltd., a small-cap commodity chemicals company transitioning into medical technology trading, delivered exceptional quarterly results for Q3 FY26 with consolidated net profit surging 6,631.03% year-on-year to ₹19.23 crores. However, the stock remains under pressure, trading at ₹38.63 with a bearish technical trend and extreme valuation multiples that raise serious questions about sustainability despite the impressive operational turnaround.

Fischer Medical Ventures Ltd, a small-cap player in the Commodity Chemicals sector, surged to hit its upper circuit limit on 30 Jan 2026, propelled by robust buying interest and a notable 4.72% intraday price gain. The stock’s performance outpaced its sector and the broader market, reflecting heightened investor enthusiasm despite a recent downgrade in its Mojo Grade to Sell.

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, recorded a fresh 52-week low of Rs.33.1 today, marking a significant milestone in its ongoing price decline. Despite a slight uptick in the stock price following two days of consecutive falls, the company’s shares remain substantially below key moving averages and continue to underperform the broader market indices.

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, touched a fresh 52-week low of Rs.33.1 today, marking a significant decline amid a challenging year for the stock. Despite a slight rebound after two days of consecutive falls, the stock remains well below its historical highs and continues to underperform its sector and benchmark indices.

Fischer Medical Ventures Ltd, a key player in the commodity chemicals sector, witnessed a sharp decline on 27 Jan 2026, hitting its lower circuit limit as panic selling gripped the stock. The share price plunged to a new 52-week low of ₹33.94, marking a maximum daily loss of 4.03%, amid heavy unfilled supply and subdued investor participation.

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, has touched a new 52-week low of Rs.33.94 today, marking a significant decline amid broader market pressures and company-specific performance factors.

Fischer Medical Ventures Ltd, a player in the Commodity Chemicals sector, recorded a new 52-week low of Rs.35.51 today, marking a significant decline in its stock price amid broader market fluctuations and company-specific performance factors.

Fischer Medical Ventures Ltd has touched a new 52-week low of Rs.35.67 today, marking a significant decline in its stock price amid broader market pressures and company-specific performance factors. This level represents a substantial drop from its 52-week high of Rs.124.20, reflecting ongoing challenges in the commodity chemicals sector and the company’s financial metrics.

Fischer Medical Ventures Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 05 Jan 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 21 January 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.